Recent advances associated with cardiometabolic remodeling in diabetes-induced heart failure
- PMID: 39453429
- PMCID: PMC11684949
- DOI: 10.1152/ajpheart.00539.2024
Recent advances associated with cardiometabolic remodeling in diabetes-induced heart failure
Abstract
Diabetes mellitus (DM) is characterized by chronic hyperglycemia, and despite intensive glycemic control, the risk of heart failure in patients with diabetes remains high. Diabetes-induced heart failure (DHF) presents a unique metabolic challenge, driven by significant alterations in cardiac substrate metabolism, including increased reliance on fatty acid oxidation, reduced glucose utilization, and impaired mitochondrial function. These metabolic alterations lead to oxidative stress, lipotoxicity, and energy deficits, contributing to the progression of heart failure. Emerging research has identified novel mechanisms involved in the metabolic remodeling of diabetic hearts, such as autophagy dysregulation, epigenetic modifications, polyamine regulation, and branched-chain amino acid (BCAA) metabolism. These processes exacerbate mitochondrial dysfunction and metabolic inflexibility, further impairing cardiac function. Therapeutic interventions targeting these pathways-such as enhancing glucose oxidation, modulating fatty acid metabolism, and optimizing ketone body utilization-show promise in restoring metabolic homeostasis and improving cardiac outcomes. This review explores the key molecular mechanisms driving metabolic remodeling in diabetic hearts, highlights advanced methodologies, and presents the latest therapeutic strategies for mitigating the progression of DHF. Understanding these emerging pathways offers new opportunities to develop targeted therapies that address the root metabolic causes of heart failure in diabetes.
Keywords: cardiac metabolism; diabetes mellitus; heart failure mechanisms; metabolic therapies; mitochondrial dysfunction.
Conflict of interest statement
No conflicts of interest, financial or otherwise, are declared by the authors.
References
-
- Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, Stein C, Basit A, Chan JCN, Claude Mbanya J, Pavkov ME, Ramachandaran A, Wild SH, James S, Herman WH, Zhang P, Bommer C, Kuo S, Boyko EJ, Magliano DJ. Erratum to “IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045” [Diabetes Res Clin Pract 183 (2022) 109119]. Diabetes Res Clin Pract 204: 110945, 2023. doi:10.1016/j.diabres.2023.110945. - DOI - PubMed
-
- Castagno D, Baird-Gunning J, Jhund PS, Biondi-Zoccai G, MacDonald MR, Petrie MC, Gaita F, McMurray JJ. Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis. Am Heart J 162: 938–948.e2, 2011. doi:10.1016/j.ahj.2011.07.030. - DOI - PubMed
-
- Pop-Busui R, Januzzi JL, Bruemmer D, Butalia S, Green JB, Horton WB, Knight C, Levi M, Rasouli N, Richardson CR. Heart failure: an underappreciated complication of diabetes. A consensus report of the American Diabetes Association. Diabetes Care 45: 1670–1690, 2022. doi:10.2337/dci22-0014. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical